Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: Secondary analysis of data from the CI-PeriNomS study

CI-PeriNomS Group

Research output: Contribution to journalArticle

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) lacks standardized clinical measurement. The objective of the current secondary analysis was to examine data from the CIPN Outcomes Standardization (CI-PeriNomS) study for associations between clinical examinations and neurophysiological abnormalities. Logistic regression estimated the strength of associations of vibration, pin, and monofilament examinations with lower limb sensory and motor amplitudes. Examinations were classified as normal (0), moderately abnormal (1), or severely abnormal (2). Among 218 participants, those with class 1 upper extremity (UE) and classes 1 or 2 lower extremity (LE) monofilament abnormality were 2.79 (95% confidence interval [CI]: 1.28-6.07), 3.49 (95%CI: 1.61-7.55), and 4.42 (95%CI: 1.35-14.46) times more likely to have abnormal sural nerve amplitudes, respectively, compared to individuals with normal examinations. Likewise, those with class 2 UE and classes 1 or 2 LE vibration abnormality were 8.65 (95%CI: 1.81-41.42), 2.54 (95%CI: 1.19-5.41), and 7.47 (95%CI: 2.49-22.40) times more likely to have abnormal sural nerve amplitudes, respectively, compared to participants with normal examinations. Abnormalities in vibration and monofilament examinations are associated with abnormal sural nerve amplitudes and are useful in identifying CIPN.

Original languageEnglish (US)
Pages (from-to)127-135
Number of pages9
JournalJournal of the Peripheral Nervous System
Volume19
Issue number2
DOIs
StatePublished - Jun 1 2014

Fingerprint

Peripheral Nervous System Diseases
Confidence Intervals
Drug Therapy
Sural Nerve
Vibration
Lower Extremity
Upper Extremity
Logistic Models

Keywords

  • Assessment
  • Chemotherapy
  • Neurophysiology
  • Peripheral neuropathy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Medicine(all)

Cite this

@article{e841e166292c444bb1349b73c94e21bf,
title = "Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: Secondary analysis of data from the CI-PeriNomS study",
abstract = "Chemotherapy-induced peripheral neuropathy (CIPN) lacks standardized clinical measurement. The objective of the current secondary analysis was to examine data from the CIPN Outcomes Standardization (CI-PeriNomS) study for associations between clinical examinations and neurophysiological abnormalities. Logistic regression estimated the strength of associations of vibration, pin, and monofilament examinations with lower limb sensory and motor amplitudes. Examinations were classified as normal (0), moderately abnormal (1), or severely abnormal (2). Among 218 participants, those with class 1 upper extremity (UE) and classes 1 or 2 lower extremity (LE) monofilament abnormality were 2.79 (95{\%} confidence interval [CI]: 1.28-6.07), 3.49 (95{\%}CI: 1.61-7.55), and 4.42 (95{\%}CI: 1.35-14.46) times more likely to have abnormal sural nerve amplitudes, respectively, compared to individuals with normal examinations. Likewise, those with class 2 UE and classes 1 or 2 LE vibration abnormality were 8.65 (95{\%}CI: 1.81-41.42), 2.54 (95{\%}CI: 1.19-5.41), and 7.47 (95{\%}CI: 2.49-22.40) times more likely to have abnormal sural nerve amplitudes, respectively, compared to participants with normal examinations. Abnormalities in vibration and monofilament examinations are associated with abnormal sural nerve amplitudes and are useful in identifying CIPN.",
keywords = "Assessment, Chemotherapy, Neurophysiology, Peripheral neuropathy",
author = "{CI-PeriNomS Group} and Griffith, {Kathleen A.} and Dorsey, {Susan G.} and Renn, {Cynthia L.} and Shijun Zhu and Johantgen, {Mary E.} and David Cornblath and Argyriou, {Andreas A.} and Guido Cavaletti and Merkies, {Ingemar S J} and Paola Alberti and Postma, {Tjeerd J.} and Emanuela Rossi and Barbara Frigeni and Jordi Bruna and Roser Velasco and Kalofonos, {Haralabos P.} and Dimitri Psimaras and Damien Ricard and Andrea Pace and Edvina Galie and Chiara Briani and {Dalla Torre}, Chiara and Faber, {Catharina G.} and Lalisang, {Roy I.} and Willem Boogerd and Dieta Brandsma and Susanne Koeppen and Joerg Hense and Storey, {Dawn J.} and Simon Kerrigan and Angelo Schenone and Sabrina Fabbri and Valsecchi, {Maria Grazia} and S. Galimberti and M. Lucchetta and M. Campagnolo and Vanhoutte, {E. K.} and M. Bakkers and B. Brouwer and R. Grant and L. Reni and B. Piras and F. Lanzani and L. Mattavelli and Piatti, {M. L.} and P. Binda and P. Bidoli and M. Cazzaniga and D. Cortinovis and A. Pessino",
year = "2014",
month = "6",
day = "1",
doi = "10.1111/jns5.12064",
language = "English (US)",
volume = "19",
pages = "127--135",
journal = "Journal of the Peripheral Nervous System",
issn = "1085-9489",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy

T2 - Secondary analysis of data from the CI-PeriNomS study

AU - CI-PeriNomS Group

AU - Griffith, Kathleen A.

AU - Dorsey, Susan G.

AU - Renn, Cynthia L.

AU - Zhu, Shijun

AU - Johantgen, Mary E.

AU - Cornblath, David

AU - Argyriou, Andreas A.

AU - Cavaletti, Guido

AU - Merkies, Ingemar S J

AU - Alberti, Paola

AU - Postma, Tjeerd J.

AU - Rossi, Emanuela

AU - Frigeni, Barbara

AU - Bruna, Jordi

AU - Velasco, Roser

AU - Kalofonos, Haralabos P.

AU - Psimaras, Dimitri

AU - Ricard, Damien

AU - Pace, Andrea

AU - Galie, Edvina

AU - Briani, Chiara

AU - Dalla Torre, Chiara

AU - Faber, Catharina G.

AU - Lalisang, Roy I.

AU - Boogerd, Willem

AU - Brandsma, Dieta

AU - Koeppen, Susanne

AU - Hense, Joerg

AU - Storey, Dawn J.

AU - Kerrigan, Simon

AU - Schenone, Angelo

AU - Fabbri, Sabrina

AU - Valsecchi, Maria Grazia

AU - Galimberti, S.

AU - Lucchetta, M.

AU - Campagnolo, M.

AU - Vanhoutte, E. K.

AU - Bakkers, M.

AU - Brouwer, B.

AU - Grant, R.

AU - Reni, L.

AU - Piras, B.

AU - Lanzani, F.

AU - Mattavelli, L.

AU - Piatti, M. L.

AU - Binda, P.

AU - Bidoli, P.

AU - Cazzaniga, M.

AU - Cortinovis, D.

AU - Pessino, A.

PY - 2014/6/1

Y1 - 2014/6/1

N2 - Chemotherapy-induced peripheral neuropathy (CIPN) lacks standardized clinical measurement. The objective of the current secondary analysis was to examine data from the CIPN Outcomes Standardization (CI-PeriNomS) study for associations between clinical examinations and neurophysiological abnormalities. Logistic regression estimated the strength of associations of vibration, pin, and monofilament examinations with lower limb sensory and motor amplitudes. Examinations were classified as normal (0), moderately abnormal (1), or severely abnormal (2). Among 218 participants, those with class 1 upper extremity (UE) and classes 1 or 2 lower extremity (LE) monofilament abnormality were 2.79 (95% confidence interval [CI]: 1.28-6.07), 3.49 (95%CI: 1.61-7.55), and 4.42 (95%CI: 1.35-14.46) times more likely to have abnormal sural nerve amplitudes, respectively, compared to individuals with normal examinations. Likewise, those with class 2 UE and classes 1 or 2 LE vibration abnormality were 8.65 (95%CI: 1.81-41.42), 2.54 (95%CI: 1.19-5.41), and 7.47 (95%CI: 2.49-22.40) times more likely to have abnormal sural nerve amplitudes, respectively, compared to participants with normal examinations. Abnormalities in vibration and monofilament examinations are associated with abnormal sural nerve amplitudes and are useful in identifying CIPN.

AB - Chemotherapy-induced peripheral neuropathy (CIPN) lacks standardized clinical measurement. The objective of the current secondary analysis was to examine data from the CIPN Outcomes Standardization (CI-PeriNomS) study for associations between clinical examinations and neurophysiological abnormalities. Logistic regression estimated the strength of associations of vibration, pin, and monofilament examinations with lower limb sensory and motor amplitudes. Examinations were classified as normal (0), moderately abnormal (1), or severely abnormal (2). Among 218 participants, those with class 1 upper extremity (UE) and classes 1 or 2 lower extremity (LE) monofilament abnormality were 2.79 (95% confidence interval [CI]: 1.28-6.07), 3.49 (95%CI: 1.61-7.55), and 4.42 (95%CI: 1.35-14.46) times more likely to have abnormal sural nerve amplitudes, respectively, compared to individuals with normal examinations. Likewise, those with class 2 UE and classes 1 or 2 LE vibration abnormality were 8.65 (95%CI: 1.81-41.42), 2.54 (95%CI: 1.19-5.41), and 7.47 (95%CI: 2.49-22.40) times more likely to have abnormal sural nerve amplitudes, respectively, compared to participants with normal examinations. Abnormalities in vibration and monofilament examinations are associated with abnormal sural nerve amplitudes and are useful in identifying CIPN.

KW - Assessment

KW - Chemotherapy

KW - Neurophysiology

KW - Peripheral neuropathy

UR - http://www.scopus.com/inward/record.url?scp=84925368982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925368982&partnerID=8YFLogxK

U2 - 10.1111/jns5.12064

DO - 10.1111/jns5.12064

M3 - Article

C2 - 24814100

AN - SCOPUS:84925368982

VL - 19

SP - 127

EP - 135

JO - Journal of the Peripheral Nervous System

JF - Journal of the Peripheral Nervous System

SN - 1085-9489

IS - 2

ER -